Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) - Analysts at HC Wainwright boosted their FY2026 earnings per share estimates for Janux Therapeutics in a research note issued to investors on Thursday, November 12th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($1.48) for the year, up from their prior estimate of ($1.69). HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Janux Therapeutics' current full-year earnings is ($1.59) per share. HC Wainwright also issued estimates for Janux Therapeutics' Q4 2026 earnings at ($0.40) EPS, Q1 2027 earnings at ($0.43) EPS, Q2 2027 earnings at ($0.45) EPS, Q3 2027 earnings at ($0.47) EPS, Q4 2027 earnings at ($0.57) EPS, FY2027 earnings at ($1.92) EPS, FY2028 earnings at ($2.75) EPS, FY2029 earnings at ($3.06) EPS and FY2030 earnings at ($2.04) EPS.
A number of other brokerages have also weighed in on JANX. Wedbush boosted their price objective on shares of Janux Therapeutics from $36.00 to $40.00 and gave the company an "outperform" rating in a report on Friday, November 6th. Weiss Ratings restated a "sell (d-)" rating on shares of Janux Therapeutics in a research note on Friday, October 16th. Truist Financial raised their target price on Janux Therapeutics from $26.00 to $27.00 and gave the stock a "buy" rating in a research note on Friday, November 6th. Barclays lifted their price target on Janux Therapeutics from $14.00 to $15.00 and gave the stock an "underweight" rating in a research report on Friday, November 6th. Finally, Guggenheim dropped their price target on Janux Therapeutics from $58.00 to $55.00 and set a "buy" rating on the stock in a research note on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $36.92.
Get Our Latest Stock Report on JANX
Janux Therapeutics Stock Performance
NASDAQ JANX opened at $11.37 on Monday. The company has a fifty day simple moving average of $16.80 and a two-hundred day simple moving average of $15.35. The stock has a market cap of $695.62 million, a P/E ratio of -7.15 and a beta of 2.44. Janux Therapeutics has a 12-month low of $11.15 and a 12-month high of $35.34.
Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.34) earnings per share for the quarter, topping analysts' consensus estimates of ($0.47) by $0.13. The business had revenue of $9.29 million for the quarter, compared to analysts' expectations of $8.03 million.
Institutional Investors Weigh In On Janux Therapeutics
Several hedge funds have recently added to or reduced their stakes in JANX. GAMMA Investing LLC raised its stake in shares of Janux Therapeutics by 67.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,642 shares of the company's stock valued at $28,000 after buying an additional 661 shares during the last quarter. Versant Capital Management Inc boosted its stake in shares of Janux Therapeutics by 42.8% in the second quarter. Versant Capital Management Inc now owns 2,615 shares of the company's stock worth $40,000 after buying an additional 784 shares during the last quarter. Fulcrum Asset Management LLP boosted its stake in shares of Janux Therapeutics by 3,391.2% in the third quarter. Fulcrum Asset Management LLP now owns 2,374 shares of the company's stock worth $40,000 after buying an additional 2,306 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Janux Therapeutics in the third quarter worth about $54,000. Finally, Quantbot Technologies LP grew its holdings in Janux Therapeutics by 2,290.0% during the second quarter. Quantbot Technologies LP now owns 5,497 shares of the company's stock worth $84,000 after acquiring an additional 5,267 shares during the period. 75.39% of the stock is owned by hedge funds and other institutional investors.
Key Headlines Impacting Janux Therapeutics
Here are a few of the latest headlines about JANX:
- Positive Sentiment: HC Wainwright raised its projected EPS for FY2026 from a loss of $1.69 to $1.48 and for FY2027 from a loss of $2.36 to $1.92. It also reduced its expected losses for each quarter from Q4 2026 through Q4 2027. The firm maintained its Buy rating. Janux Therapeutics coverage
- Negative Sentiment: Longer-term forecasts were cut: FY2029 EPS moved from a loss of $1.11 to a loss of $3.06, while FY2030 shifted from projected earnings of $0.97 to a loss of $2.04. The FY2028 loss estimate also edged wider, from $2.72 to $2.75 per share, signaling a less favorable long-range outlook. Janux Therapeutics coverage
About Janux Therapeutics
(
Get Free Report)
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for cancer. The company's research focuses on engaging a patient's T cells to recognize and attack tumors. Janux's proprietary platforms are designed to keep certain immune therapies inactive until they reach the tumor environment, with the goal of limiting activity in healthy tissues. Its clinical-stage programs include candidates directed at targets such as PSMA and EGFR, and its broader pipeline includes additional investigational cancer therapies.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Janux Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Janux Therapeutics wasn't on the list.
While Janux Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.